Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO Sarcoma and Rare Cancers 2023 | Elucidating the limitations and future prospects of the PerSARC model

Michiel Van De Sande, MD, PhD, Leiden University Medical Center, Leiden, Netherlands, discusses the current obstacles when it comes to predicting overall survival (OS) and disease recurrence in patients with severe comorbidities in addition to soft tissue sarcoma. Prof. Van De Sande expresses that future advancements of this model should consider the presence of comorbidities to ascertain better survival estimates as well as the importance of quality of life estimates following a particular course of therapy. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.